Polygenic Risk Score Services Market Report 2026

The polygenic risk score services market size has grown rapidly in recent years. It will grow from $1.45 billion in 2025 to $1.69 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to expansion of large-scale genotyping studies, increasing availability of genomic databases, growth in preventive healthcare initiatives, rising interest in genetic risk assessment, advances in statistical genetics methods.

The polygenic risk score services market size is expected to see rapid growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to increasing clinical adoption of risk stratification tools, rising integration of prs into personalized medicine, expansion of preventive genomics programs, growing demand for interoperable genetic data platforms, increasing regulatory clarity for genetic services. Major trends in the forecast period include increasing adoption of polygenic risk prediction algorithms, rising integration of prs with clinical decision tools, growing demand for population-specific risk models, expansion of direct-to-consumer genetic risk services, enhanced focus on data security and privacy.

The growing emphasis on personalized medicine is expected to propel the growth of the polygenic risk score (PRS) services market going forward. Advances in genomics enable disease risk prediction using genetic data. PRS services estimate disease risk and guide preventive strategies. For instance, FDA approvals for personalized treatments increased in 2023. Therefore, growing emphasis on personalized medicine is driving the growth of the PRS services market.

Leading companies operating in the polygenic risk score services market are focusing on developing innovative solutions such as pharmacogenomics to enhance personalized treatment strategies and improve patient outcomes. Pharmacogenomics is the study of how an individual’s genetic profile influences drug response, enabling more accurate and personalized therapeutic approaches. For instance, in July 2025, Bupa, a UK-based health insurance company, launched a new suite of DNA-based tests designed to support personalized health and wellness insights. This suite provides individualized information on medication response and disease risk, enabling earlier detection and tailored treatment for conditions including cancer, diabetes, and cardiovascular disease. These tests help reduce adverse drug reactions, improve long-term health outcomes, and empower individuals to take proactive steps for themselves and their families, supporting a transition from reactive care to preventive, precision health management.

In May 2024, GSK Plc, a UK-based pharmaceutical company, partnered with Genomics Ltd. to advance genetic research and develop personalized therapies. Through this partnership, GSK aims to leverage polygenic risk scores to optimize clinical trial design by selecting appropriate patients, reducing trial size and duration, and improving drug development efficiency. Genomics Ltd. is a UK-based precision medicine company providing polygenic risk score services.

Major companies operating in the polygenic risk score services market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Illumina Inc., Endeavor Health Inc., Myriad Genetics Inc., The Broad Institute of MIT and Harvard, BGI Group, Invitae Corporation, 23andMe Holding Co., Color Health Inc., Genomics Ltd., Cogentech S.R.L., Gene by Gene Ltd., Our Future Health Ltd., Mapmygenome India Limited, Australian Genome Research Facility (AGRF) Ltd., Golden Helix Inc., Allelica Inc., Antegenes OÜ, GeninCode Plc.

North America was the largest region in the polygenic risk score services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polygenic risk score services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polygenic risk score services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the polygenic risk score services market by increasing costs of imported sequencing equipment, genotyping arrays, cloud infrastructure components, and advanced analytics software. Healthcare providers and genomics companies in North America and Europe are most affected due to dependence on imported technologies, while Asia-Pacific faces increased costs for large-scale genetic testing deployments. These tariffs are raising service pricing and slowing expansion efforts. However, they are also promoting domestic development of analytics platforms, regional cloud infrastructure growth, and localized genetic testing capabilities.

The polygenic risk score services market research report is one of a series of new reports that provides polygenic risk score services market statistics, including polygenic risk score services industry global market size, regional shares, competitors with a polygenic risk score services market share, detailed polygenic risk score services market segments, market trends and opportunities, and any further data you may need to thrive in the polygenic risk score services industry. This polygenic risk score services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polygenic risk score (PRS) services are solutions that determine an individual’s probability of developing certain diseases or conditions by analyzing the combined influence of multiple genetic variants across the genome. These services process DNA data, typically derived from genotyping or sequencing, and apply statistical models to calculate a personalized risk score.

The primary service types of polygenic risk score services are genotyping, sequencing, data analysis, reporting, and others. Genotyping involves identifying genetic differences by examining an individual’s DNA using biological assays. These services are applied in disease risk evaluation, personalized medicine, research, and other areas, serving end-users such as hospitals and clinics, research institutes, direct-to-consumer providers, and others.

The polygenic risk score (PRS) services market includes revenues earned by entities providing services such as polygenic risk scoring, genetic testing, data analysis and interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.